Aspire Biopharma Holdings (ASBP) Consolidated Net Income (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has 3 years of Consolidated Net Income data on file, last reported at -$3.2 million in Q1 2026.

• On a quarterly basis, Consolidated Net Income rose 79.78% year-over-year to -$3.2 million in Q1 2026; TTM through Mar 2026 was -$13.9 million, a 16.84% increase from a year earlier, with the FY2025 full-year figure at -$19.3 million, down 1376.47% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$3.2 million, up from -$8.1 million in the prior quarter.
• Over the last five years, Consolidated Net Income for ASBP reached as high as -$216269.0 in Q3 2024 and fell as low as -$15.9 million in Q1 2025.
• Historically, Consolidated Net Income has averaged -$5.1 million across 3 years, with a median of -$2.9 million in 2025.
• Across the five-year window, Consolidated Net Income plunged 1257.0% in 2025 and soared 79.78% in 2026, its largest moves.
• Year by year, Consolidated Net Income stood at -$595639.0 in 2024, then plunged by 1257.0% to -$8.1 million in 2025, then soared by 60.13% to -$3.2 million in 2026.
• Per Business Quant data, the three most recent Consolidated Net Income figures were -$3.2 million in Q1 2026, -$8.1 million in Q4 2025, and -$2.6 million in Q3 2025.